NKLR

Terra Innovatum Global N.V. (NKLR) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Terra Innovatum Global N.V. is a development-stage nuclear energy technology company focused on the engineering, regulatory engagement, and future commercialization of the SOLO™ Micro-Modular Nuclear Reactor. The company completed a business combination with GSR III Acquisition Corp. in October 2025 and trades on Nasdaq under the symbol NKLR. As of the reporting date, the company has not generated revenue from operations and remains in the pre-commercialization phase.

Key Financial Metrics

Debt and Liquidity: The company has no traditional senior debt. However, it carries significant non-current liabilities, including a $185.9 million share-settled contingent liability and $9.9 million in warrant liabilities. Liquidity is supported by cash proceeds from the October 2025 business combination.

Material Changes vs. Prior Period

• Operating Expenses: Increased by 358% to $6.6 million from $1.4 million. This was driven by a 281% increase in General and Administrative expenses (primarily third-party compensation and insurance) and a 3,652% increase in Development costs (primarily technical consultancy fees).
• Net Loss: Widened significantly to $7.1 million from $1.4 million. The increase was primarily due to higher operating expenses and a $3.3 million unrealized loss from the change in fair value of the share-settled contingent liability.
• Other Income: Increased to $2.8 million (from $1) due to net foreign currency transaction gains of approximately $2.2 million and interest income.
• Cash Position: Cash decreased by $4.2 million during the quarter, primarily due to operating cash burn and the impact of foreign exchange rate changes.

Outlook, Risks, and Management Commentary

• Commercialization Timeline: Management targets commercial deployment of the SOLO reactor by 2028. The company is currently engaged in pre-application activities with the U.S. Nuclear Regulatory Commission (NRC).
• Capital Needs: The company explicitly states it will require substantial additional capital to complete development and achieve commercialization. There is no assurance that financing will be available on acceptable terms.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to four material weaknesses. These include insufficient SOX control environment, lack of formal risk assessment post-de-SPAC, failure to uplift internal controls, and lack of a monitoring program. A remediation plan is underway.
• Risks: Key risks include the complexity of nuclear regulatory approval, dependence on external funding, global supply chain vulnerabilities, and macroeconomic inflation affecting development costs.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $96.7 million cash balance against the current burn rate of ~$3.9 million per quarter to assess the timeline for the next capital raise.
• Contingent Liabilities: Review the valuation assumptions (volatility, probability of milestones) for the $185.9 million share-settled contingent liability, as changes in these inputs significantly impact reported net loss.
• Regulatory Progress: Monitor updates on the NRC pre-application engagement, as delays could materially impact the 2028 commercialization target.
• Internal Control Remediation: Track the progress of the remediation plan for the four identified material weaknesses in internal controls over financial reporting.
• Related Party Transactions: Review ongoing agreements with related parties (e.g., Nine Nuclear and Industrial Engineering S.R.L.) for engineering services and leases to ensure terms are arm's length.